Screener
MBX Biosciences, Inc. MBX Operating Income
Operating Income at other companies
Other financials
Where this comes from
Reported directly by MBX Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingIncomeLoss.
The source filing: MBX Biosciences, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 9:03 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210593
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Research and development | $18,474 | $22,405 |
| General and administrative | 8,791 | 4,124 |
| Total operating expenses | 27,265 | 26,529 |
| Loss from operations | (27,265) | (26,529) |
| Interest and other income, net | 3,748 | 2,649 |
| Net loss | $(23,517) | $(23,880) |
| Unrealized loss on marketable securities | (892) | (2) |
| Total other comprehensive loss | (892) | (2) |
Item 1. Financial Statements.
FAQ
- What is MBX Biosciences, Inc.'s operating income?
- MBX Biosciences, Inc. (MBX) reported operating income of -$27.27M in Q1 2026.
- How has MBX Biosciences, Inc.'s operating income changed year-over-year?
- MBX Biosciences, Inc.'s operating income decreased by 2.8% year-over-year, from -$26.53M to -$27.27M.
- What does operating income mean?
- Gross profit minus all operating expenses (SG&A, R&D, D&A). Measures the profit from core business operations before interest, taxes, and non-operating items.
Ask your AI about MBX Biosciences, Inc.'s operating income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude